<style face="normal" font="default" size="100%">437 Optimised achilles VELOS<sup>TM</sup> process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer</style>

Drupal-HighWire